Related Experiment Video
Updated: Aug 5, 2026
12:05
Database-guided Flow-cytometry for Evaluation of Bone Marrow Myeloid Cell Maturation
Published on: November 3, 2018
Immunologic indices in myelodysplastic syndromes
P H Colombat1, M Renoux, J P Lamagnere
1Department of Hematology, CHU Bretonneau, Tours, France.
Cancer
|March 15, 1988
Summary
Myelodysplastic syndromes (MDS) are linked to weakened immune function, particularly T-cell deficiencies. Higher T3 and T8 cell counts may indicate a better prognosis for MDS patients.
Area of Science:
- Immunology
- Hematology
Background:
- Myelodysplastic syndromes (MDS) are a group of clonal hematopoietic stem cell disorders.
- Assessing immunocompetence in MDS patients is crucial for understanding disease progression and prognosis.
Purpose of the Study:
- To evaluate the immunocompetence of patients with myelodysplastic syndromes (MDS).
- To investigate the correlation between immune cell counts and clinical outcomes in MDS.
Main Methods:
- Evaluated T-cell number and activity (total T-cells, subsets, DNA synthesis).
- Assessed B-cells (surface immunoglobulin-bearing cells, serum immunoglobulin levels).
- Measured granulocyte activity (chemotaxis, nitroblue tetrazolium test) and complement activity.
Main Results:
- MDS patients showed decreased T-cell numbers (T3+, T4+, T8+) and reduced response to Concanavalin A.
- Impaired granulocyte function (chemotaxis, NBT test) and elevated IgG/IgA levels were common.
- Severe T-cell impairment correlated with refractory anemia and excess medullary blast cells.
Conclusions:
- MDS is associated with significant immune system deficiencies, particularly affecting T-cells.
- Absolute counts of T3+ and T8+ cells may serve as valuable prognostic markers in MDS.
- Immune status evaluation provides insights into MDS pathophysiology and patient survival.
